vs
Net Lease Office Properties（NLOP）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Net Lease Office Properties的季度营收约是REGENXBIO Inc.的1.0倍（$30.7M vs $30.3M），Net Lease Office Properties净利率更高（-0.2% vs -221.3%，领先221.2%），REGENXBIO Inc.同比增速更快（43.0% vs 10.9%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -16.4%）
Net Lease Office Properties是一家商业地产投资机构，主要收购、持有并运营美国境内的优质单一租户净租赁办公资产，通过其精选的商业地产投资组合，为投资者提供长期稳定的收益渠道。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
NLOP vs RGNX — 直观对比
营收规模更大
NLOP
是对方的1.0倍
$30.3M
营收增速更快
RGNX
高出32.1%
10.9%
净利率更高
NLOP
高出221.2%
-221.3%
两年增速更快
RGNX
近两年复合增速
-16.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $30.7M | $30.3M |
| 净利润 | $-53.0K | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | -0.2% | -190.0% |
| 净利率 | -0.2% | -221.3% |
| 营收同比 | 10.9% | 43.0% |
| 净利润同比 | 99.9% | -31.2% |
| 每股收益（稀释后） | $-0.01 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NLOPRGNX
| Q4 25 | $30.7M | $30.3M | ||
| Q3 25 | $29.8M | $29.7M | ||
| Q2 25 | $29.2M | $21.4M | ||
| Q1 25 | $29.2M | $89.0M | ||
| Q4 24 | $27.7M | $21.2M | ||
| Q3 24 | $31.5M | $24.2M | ||
| Q2 24 | $39.0M | $22.3M | ||
| Q1 24 | $44.0M | $15.6M |
净利润NLOPRGNX
| Q4 25 | $-53.0K | $-67.1M | ||
| Q3 25 | $-64.2M | $-61.9M | ||
| Q2 25 | $-81.5M | $-70.9M | ||
| Q1 25 | $492.0K | $6.1M | ||
| Q4 24 | $-35.8M | $-51.2M | ||
| Q3 24 | $-40.3M | $-59.6M | ||
| Q2 24 | $12.5M | $-53.0M | ||
| Q1 24 | $-27.8M | $-63.3M |
毛利率NLOPRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率NLOPRGNX
| Q4 25 | -0.2% | -190.0% | ||
| Q3 25 | -215.2% | -176.3% | ||
| Q2 25 | -279.1% | -296.3% | ||
| Q1 25 | 2.0% | 13.6% | ||
| Q4 24 | -140.7% | -242.1% | ||
| Q3 24 | -126.4% | -256.6% | ||
| Q2 24 | 32.3% | -251.3% | ||
| Q1 24 | -62.7% | -408.8% |
净利率NLOPRGNX
| Q4 25 | -0.2% | -221.3% | ||
| Q3 25 | -215.4% | -208.3% | ||
| Q2 25 | -279.5% | -331.8% | ||
| Q1 25 | 1.7% | 6.8% | ||
| Q4 24 | -129.0% | -241.3% | ||
| Q3 24 | -128.0% | -246.3% | ||
| Q2 24 | 31.9% | -237.7% | ||
| Q1 24 | -63.3% | -405.4% |
每股收益（稀释后）NLOPRGNX
| Q4 25 | $-0.01 | $-1.30 | ||
| Q3 25 | $-4.33 | $-1.20 | ||
| Q2 25 | $-5.50 | $-1.38 | ||
| Q1 25 | $0.03 | $0.12 | ||
| Q4 24 | $-2.41 | $-0.99 | ||
| Q3 24 | $-2.73 | $-1.17 | ||
| Q2 24 | $0.84 | $-1.05 | ||
| Q1 24 | $-1.88 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $119.6M | $230.1M |
| 总债务越低越好 | $21.9M | — |
| 股东权益账面价值 | $293.9M | $102.7M |
| 总资产 | $453.4M | $453.0M |
| 负债/权益比越低杠杆越低 | 0.07× | — |
8季度趋势，按日历期对齐
现金及短期投资NLOPRGNX
| Q4 25 | $119.6M | $230.1M | ||
| Q3 25 | $38.7M | $274.2M | ||
| Q2 25 | $54.1M | $323.3M | ||
| Q1 25 | $28.2M | $267.9M | ||
| Q4 24 | $25.1M | $234.7M | ||
| Q3 24 | $36.1M | $255.5M | ||
| Q2 24 | $36.1M | $290.4M | ||
| Q1 24 | $39.8M | $338.7M |
总债务NLOPRGNX
| Q4 25 | $21.9M | — | ||
| Q3 25 | $47.1M | — | ||
| Q2 25 | $117.2M | — | ||
| Q1 25 | $148.5M | — | ||
| Q4 24 | $169.2M | — | ||
| Q3 24 | $239.4M | — | ||
| Q2 24 | $327.4M | — | ||
| Q1 24 | $515.2M | — |
股东权益NLOPRGNX
| Q4 25 | $293.9M | $102.7M | ||
| Q3 25 | $430.3M | $161.5M | ||
| Q2 25 | $500.0M | $213.7M | ||
| Q1 25 | $582.1M | $274.2M | ||
| Q4 24 | $581.2M | $259.7M | ||
| Q3 24 | $621.9M | $301.4M | ||
| Q2 24 | $660.3M | $348.3M | ||
| Q1 24 | $647.2M | $390.7M |
总资产NLOPRGNX
| Q4 25 | $453.4M | $453.0M | ||
| Q3 25 | $522.6M | $525.2M | ||
| Q2 25 | $668.7M | $581.0M | ||
| Q1 25 | $784.1M | $490.9M | ||
| Q4 24 | $805.1M | $466.0M | ||
| Q3 24 | $919.9M | $519.1M | ||
| Q2 24 | $1.0B | $569.4M | ||
| Q1 24 | $1.2B | $629.2M |
负债/权益比NLOPRGNX
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.11× | — | ||
| Q2 25 | 0.23× | — | ||
| Q1 25 | 0.26× | — | ||
| Q4 24 | 0.29× | — | ||
| Q3 24 | 0.38× | — | ||
| Q2 24 | 0.50× | — | ||
| Q1 24 | 0.80× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $64.1M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流NLOPRGNX
| Q4 25 | $64.1M | $-52.3M | ||
| Q3 25 | $16.3M | $-56.0M | ||
| Q2 25 | $11.7M | $-49.3M | ||
| Q1 25 | $14.1M | $33.6M | ||
| Q4 24 | $71.9M | $-31.6M | ||
| Q3 24 | $20.3M | $-40.5M | ||
| Q2 24 | $14.7M | $-45.5M | ||
| Q1 24 | $26.4M | $-55.5M |
自由现金流NLOPRGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率NLOPRGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度NLOPRGNX
| Q4 25 | — | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率NLOPRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 28.70× | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.18× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NLOP
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
